<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273323</url>
  </required_header>
  <id_info>
    <org_study_id>REF-BEV-1376</org_study_id>
    <nct_id>NCT02273323</nct_id>
  </id_info>
  <brief_title>Flow Mediated Dilation in Response to Black Tea</brief_title>
  <acronym>T</acronym>
  <official_title>Flow Mediated Dilation in Response to Consumption of Black Tea Versus Artificial Tea, in Non-tea Drinking Hypertensive Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unilever R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research indicate that people who regularly drink tea have a reduced risk of stroke or heart
      disease. In a number of studies in which people that normally do not drink showed that their
      blood vessels function improved when the drunk tea. The current study tests whether a
      specific black tea improves vessel function in non-tea drinking hypertensive subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological studies indicate that regular consumption of three cups of black tea per day
      reduces the risk of stroke or myocardial infarction. In a number of previous nutrition
      intervention studies tea has been shown to improve vascular function as assessed by Flow
      Mediated Dilation in various populations. The current confirmatory study tests a specific
      black tea against a placebo in a population of in non-tea drinking hypertensive subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Dilation</measure>
    <time_frame>Before and 2 hours after test product intake</time_frame>
    <description>Flow mediated dilation (FMD) of the brachial artery was measured using vascular ultra sound and automated edge detection software:
1 minute baseline scan to measure the baseline diameter of artery
5 minutes of forearm occlusion at 250±30 mmHg, below the elbow (2-5 cm from antecubital crease)
4 minutes FMD scan, which started immediately after release of occlusion Percentage FMD was calculated as the maximum increase in diameter after cuff release relative to the baseline diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelium-independent Vasodilation</measure>
    <time_frame>2.5 hours after test product intake</time_frame>
    <description>Endothelium-independent dilation after glyceryl trinitrate defined as maximal percent increase in diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure Supine</measure>
    <time_frame>Before and 110 minutes after test product intake</time_frame>
    <description>Systolic blood pressure measured while lying down</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure Supine</measure>
    <time_frame>Before and 110 minutes after test product intake</time_frame>
    <description>Diastolic blood pressure measured while lying down</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure Sitting</measure>
    <time_frame>Before and 90 minutes after test product intake</time_frame>
    <description>Systolic blood pressure measured while sitting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure Sitting</measure>
    <time_frame>Before and 90 minutes after test product intake</time_frame>
    <description>Diastolic blood pressure measured while sitting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Vascular Function</condition>
  <arm_group>
    <arm_group_label>Tea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Black tea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tea</intervention_name>
    <description>Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.</description>
    <arm_group_label>Tea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: tea flavour, colouring and sugar</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and post menopausal (&gt; 1 year) females, not on hormone replacement therapy

          -  Aged &gt;18 and &lt; 65 years

          -  Body mass index (BMI) of &gt;=18.0 and =&lt;35.0 kg/m2

          -  Hypertension as previously diagnosed by primary care or hospital physician.

               -  If untreated, office BP between 140/90 mmHg and 160/100 mmHg on screening

               -  If treated, a controlled blood pressure (&lt;160/100) on stable medication for at
                  least 4 weeks

        Exclusion Criteria:

          -  Tea drinkers: having typically consumed &gt; 1 cup of black tea per week.

          -  Current smoker or has stopped smoking less than 6 months before start of study

          -  Self reported alcohol intake of &gt;21 units/week

          -  Established cardiovascular disease other than hypertension

          -  Clinically significant arrhythmia

          -  Diabetes mellitus

          -  Chronic Kidney Disease &gt; stage 2

          -  10-year cardiovascular risk equivalent to 20% or greater using the QRisk2 calculator

          -  Abnormality of laboratory blood tests considered clinically significant

          -  Any other significant intercurrent condition/disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Chowienczyk, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Clinical Pharmacology/CRF, St Thomas Hospital, London UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Clinical Pharmacology/CRF, St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>December 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2017</results_first_posted>
  <last_update_submitted>December 21, 2016</last_update_submitted>
  <last_update_submitted_qc>December 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flow mediated dilation</keyword>
  <keyword>tea</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>53 subjects were screened between August 2014 and and October 2015</recruitment_details>
      <pre_assignment_details>All 30 subjects meeting the inclusion criteria were randomised</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tea Then Placebo</title>
          <description>Subjects first received a single acute dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar. After a washout of at least 1 week, they received a single acute dose of placebo consisting of tea flavour, colouring and sugar.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Tea</title>
          <description>Subjects first received a single acute dose of placebo consisting of tea flavour, colouring and sugar. After a washout of at least 1 week, they received a single acute dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomised to either receive Tea first followed by Placebo or Placebo first followed by Tea</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="23" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" lower_limit="19.8" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145" lower_limit="119" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92" lower_limit="67" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow Mediated Dilation</title>
        <description>Flow mediated dilation (FMD) of the brachial artery was measured using vascular ultra sound and automated edge detection software:
1 minute baseline scan to measure the baseline diameter of artery
5 minutes of forearm occlusion at 250±30 mmHg, below the elbow (2-5 cm from antecubital crease)
4 minutes FMD scan, which started immediately after release of occlusion Percentage FMD was calculated as the maximum increase in diameter after cuff release relative to the baseline diameter</description>
        <time_frame>Before and 2 hours after test product intake</time_frame>
        <population>All participants who received at least one dose of each intervention and completed all study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tea Beverage</title>
            <description>Participants when they received a single dose of black tea infusion with added sugar</description>
          </group>
          <group group_id="O2">
            <title>Placebo Beverage</title>
            <description>Participants when they received a single dose of placebo containing tea flavour, colouring and sugar</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Mediated Dilation</title>
          <description>Flow mediated dilation (FMD) of the brachial artery was measured using vascular ultra sound and automated edge detection software:
1 minute baseline scan to measure the baseline diameter of artery
5 minutes of forearm occlusion at 250±30 mmHg, below the elbow (2-5 cm from antecubital crease)
4 minutes FMD scan, which started immediately after release of occlusion Percentage FMD was calculated as the maximum increase in diameter after cuff release relative to the baseline diameter</description>
          <population>All participants who received at least one dose of each intervention and completed all study visits</population>
          <units>percentage of change in diameter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FMD before test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="2.42"/>
                    <measurement group_id="O2" value="5.02" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FMD two hours after test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="2.33"/>
                    <measurement group_id="O2" value="5.74" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated effect of tea vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>0.23</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelium-independent Vasodilation</title>
        <description>Endothelium-independent dilation after glyceryl trinitrate defined as maximal percent increase in diameter</description>
        <time_frame>2.5 hours after test product intake</time_frame>
        <population>All participants who received at least one dose of each intervention and completed all study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tea Beverage</title>
            <description>Participants when they received a single dose of black tea infusion with added sugar</description>
          </group>
          <group group_id="O2">
            <title>Placebo Beverage</title>
            <description>Participants when they received a single dose of placebo containing tea flavour, colouring and sugar</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelium-independent Vasodilation</title>
          <description>Endothelium-independent dilation after glyceryl trinitrate defined as maximal percent increase in diameter</description>
          <population>All participants who received at least one dose of each intervention and completed all study visits</population>
          <units>percentage of change in diameter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="10.6" upper_limit="13.6"/>
                    <measurement group_id="O2" value="11.4" lower_limit="9.9" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated effect of tea vs. placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Subject=random factor; treatment, on/off medication, period = fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure Supine</title>
        <description>Systolic blood pressure measured while lying down</description>
        <time_frame>Before and 110 minutes after test product intake</time_frame>
        <population>All participants who received at least one dose of each intervention and completed all study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tea Beverage</title>
            <description>Participants when they received a single dose of black tea infusion with added sugar</description>
          </group>
          <group group_id="O2">
            <title>Placebo Beverage</title>
            <description>Participants when they received a single dose of placebo containing tea flavour, colouring and sugar</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure Supine</title>
          <description>Systolic blood pressure measured while lying down</description>
          <population>All participants who received at least one dose of each intervention and completed all study visits</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.5" spread="14.2"/>
                    <measurement group_id="O2" value="138.1" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.0" spread="16.2"/>
                    <measurement group_id="O2" value="147.2" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.26</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure Supine</title>
        <description>Diastolic blood pressure measured while lying down</description>
        <time_frame>Before and 110 minutes after test product intake</time_frame>
        <population>All participants who received at least one dose of each intervention and completed all study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tea Beverage</title>
            <description>Participants when they received a single dose of black tea infusion with added sugar</description>
          </group>
          <group group_id="O2">
            <title>Placebo Beverage</title>
            <description>Participants when they received a single dose of placebo containing tea flavour, colouring and sugar</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure Supine</title>
          <description>Diastolic blood pressure measured while lying down</description>
          <population>All participants who received at least one dose of each intervention and completed all study visits</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" spread="10.2"/>
                    <measurement group_id="O2" value="85.7" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" spread="10.9"/>
                    <measurement group_id="O2" value="89.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure Sitting</title>
        <description>Systolic blood pressure measured while sitting</description>
        <time_frame>Before and 90 minutes after test product intake</time_frame>
        <population>All participants who received at least one dose of each intervention and completed all study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tea Beverage</title>
            <description>Participants when they received a single dose of black tea infusion with added sugar</description>
          </group>
          <group group_id="O2">
            <title>Placebo Beverage</title>
            <description>Participants when they received a single dose of placebo containing tea flavour, colouring and sugar</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure Sitting</title>
          <description>Systolic blood pressure measured while sitting</description>
          <population>All participants who received at least one dose of each intervention and completed all study visits</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.7" spread="13.7"/>
                    <measurement group_id="O2" value="137.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.4" spread="13.1"/>
                    <measurement group_id="O2" value="148.5" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.65</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure Sitting</title>
        <description>Diastolic blood pressure measured while sitting</description>
        <time_frame>Before and 90 minutes after test product intake</time_frame>
        <population>All participants who received at least one dose of each intervention and completed all study visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tea Beverage</title>
            <description>Participants when they received a single dose of black tea infusion with added sugar</description>
          </group>
          <group group_id="O2">
            <title>Placebo Beverage</title>
            <description>Participants when they received a single dose of placebo containing tea flavour, colouring and sugar</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure Sitting</title>
          <description>Diastolic blood pressure measured while sitting</description>
          <population>All participants who received at least one dose of each intervention and completed all study visits</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" spread="10.3"/>
                    <measurement group_id="O2" value="87.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After test product intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" spread="10.5"/>
                    <measurement group_id="O2" value="89.4" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tea Beverage</title>
          <description>Participants when they received a single dose of black tea infusion with added sugar</description>
        </group>
        <group group_id="E2">
          <title>Placebo Beverage</title>
          <description>Participants when they received a single dose of placebo containing tea flavour, colouring and sugar</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theo Mulder</name_or_title>
      <organization>Unilever R&amp;D Vlaardingen</organization>
      <phone>+31 10 460 8315</phone>
      <email>theo.mulder@unilever.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

